Highlights from IMW 2019

19-20 novembre 2019
Bologna
Royal Hotel Carlton

Immunoterapia cellulare adottiva (CAR-T) e anticorpi monoclonali (bi-specifici e coniugati)

CAR-T anti BCMA

Elena Zamagni

ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

ALMA MATER STUD
UNIVERSITÀ DI BO

Seràgnoli Institute of Hematology
Bologna University School of Medicine

Honoraria e membro di advisory board per Celgene, Janssen, BMS, Takeda, Amgen

MAMMOTH study
suboptimal outcomes in patients refractory to anti-CD38 monoclonal antibodies

275 patients refractory to anti-CD38 mAbs

	Median OS months	
Not triple refractory	11.2	Refractory to 1 CD38 mAb, and not both PI and IMiD
Triple and quad refractory	9.2	Refractory to 1 CD38 mAb + 1 PI + 1 or 2 IMiD compounds, etc.
Penta refractory	5.6	Refractory to 1 CD38 mAb + 2 PIs + 2 IMiD compounds
Overall cohort	8.6	



249 patients received further treatment
ORR 31%
mPFS 3.4 months
mOS 9.3 months

Unmet clinical need!

Gandhi UH et al., *Leukemia*. 2019

Innovative strategies are needed to overcome refractoriness to conventional drugs



Rodríguez-Otero P, et al. Haematologica. 2017;102:423-32.

Surface antigens on clonal plasma cells



[a]Approved by the FDA and EMA.
BCMA, B-cell maturation antigen; IL-6, interleukin-6; PD-L1, programmed cell death-ligand; RANKL, receptor activator of nuclear factor kappa-B ligand.

Bhatnagar V, et al. Oncologist. 2017;22:1347-53. Gormley NJ, et al. Clin Cancer Res. 2017;23:6759-63. Jelinek T, et al. Front Immunol. 2018;9:2431. Moreno L, et al. Clin Cancer Res. 2019;epub. Raab MS, et al. Blood. 2016;128:1152. Rawstron AC, et al. Haematologica. 2008;93:431-8. Smith EL et al. Sci Tras Med 2019; 11(485).

BCMA: a good target





- BCMA is an antigen expressed specifically on PCs and myeloma cells
  - Member of TNFR superfamily. Binds 2 ligands (BAFF e APRIL)
  - higher expression in myeloma cells than normal PCs
  - key role in B-cell maturation and differentiation
  - promotes myeloma cell growth, chemoresistance, and immunosuppression in the BM microenvironment
- Expression of BCMA increases as the disease progresses from MGUS to advanced myeloma

APRIL, a proliferation-inducing ligand; BAFF-R, B-cell activating factor receptor; GC, germinal centre; LN, lymph node; MGUS, monoclonal gammopathy of unknown significance; sBCMA, soluble BCMA; TACI, transmembrane activator and CAML interactor.

Cho SF, et al. Front Immunol. 2018;9:1821. Moreaux J, et al. Blood. 2004;103:3148-57. Sanchez E, et al. Br J Haematol. 2012;158:727-38.

BCMA CAR T cells in MM

46 clinical trials with BCMA CAR T in clinicaltrials.gov

Trial site	ScFv	Co-s domain	Gene transfer	Conditioning therapy	T-cell dose CAR+ T cells/kg
NCI[1,2]	11D5-3	**CD28**	**ϒ- retroviral**	Cy 300 mg/m^2 × 3 + Flu 30 mg/m^2 × 3	0.3–9.0 × 10^6
	NR, murine	4-1BB	Lentiviral	Cy 300 mg/m^2 × 3 + Flu 30 mg/m^2 × 3	50, 150, 450, and 800 × 10^6
University of Pennsylvania[4]	NR, human	4-1BB	Lentiviral	**None or Cy 1.5 g/m^2**	10–50 × 10^6 or 100–500 × 10^6
	NR, human	4-1BB	Lentiviral	**Cy 300 mg/m^2 × 3**	1.5–7.0 × 10^6
MSKCC[7,8]	NR, human	4-1BB	**ϒ- retroviral**	Cy 3000 mg/m^2 or Cy 300 mg/m^2 × 3 + Flu 30 mg/m^2 × 3	1, 150, 450, and 800 × 10^6
Poseida[9]	NR[a], human	4-1BB	Transposon	Cy 300 mg/m^2 × 3 + Flu 30 mg/m^2 × 3	0.75, 2, 6, 10, and 15 × 10^6

[a] Small human ibronectin domain.
Cy, cyclophosphamide; Flu, fludarabine.

1. Brudno JN, et al. J Clin Oncol. 2018;36:2267-80. 2. Ali SA, et al. Blood. 2016;128:1688-700. 3. Berdeja JG, et al. Blood. 2017;130:740. 4. Cohen AD, et al. Blood. 2017;130:505. 5. Aili H, et al. EHA abstract. 6. Fan FX, et al. J Clin Oncol. 2017;35:18. 7. Smith EL, et al. Blood. 2017;130:742. 8. Hermanson DL, et al. Blood. 2016. 9. Gregory T, et al. Blood. 2018;132:1012. Presented at ASH 2018.

BCMA-CAR T cells in MM
Phase I study NCI: efficacy (N = 16)

Study Design:

- **Cy** 300mg/mq + **Flu** 30mg/mq gg -5, -4, -3
- **Dose escalation: 0.3 x 10^6** CART cells/kg → **1 x 10^6 → 3 x 10^6 → 9 x 10^6**

ORR: 13/16 (81%) at 9 × 10^6 cells/kg dose level

11/14 (79%) evaluable pts at 9 × 10^6 cells/kg achieved MRD-neg status



Median EFS = 31 weeks

(6 pts with ongoing response)



CRS minimal at lower doses but substantial at 9 × 10^6/kg

- 6 pts grade 3–4 CRS
- 10 pts grade 1–2 CRS
- 5/16 pts (31%) received tocilizumab
- 4/16 pts (25%) received steroids

Brudno JN, et al. J Clin Oncol. 2018;36:2267-80.

CAR-T cell therapy (and other T-cell redirected therapies): unique acute toxicities

- Cytokine release syndrome (CRS)
  - Inflammatory process related to exponential T cell proliferation and activation
  - Release of supra-physiological levels of pro-inflammatory cytokines (e.g, IL-6, INFγ, TNFα)
  - IL-6 believed to be central mediator
- Time to onset: expected in first 14 days (mostly first 7 days)
- Fever, hypotension, hypoxia, multi-organ failure
- Diagnosed based on clinical symptoms; CRP used as surrogate

- Encephalopathy/Neurological toxicity
  - Exact mechanism remains unclear but pathophysiology thought to include endothelial activation/dysfunction and microangiopathy
  - May occur together with CRS or independently (after CRS).
  - Time to onset: expected in first 14 days
  - Diminished attention, language disturbance, confusion, disorientation, and occasionally seizures/cerebral oedema , delirium

Neelapu Nat Rev Clin Oncol 2018 Jan;15(1):47-62; Drent PloS One 2018

BCMA CAR-T
Phase I trial

- Lentiviral vector-based + 4-1BB co-stimulatory domain
- **Fully human** scFV fused to hinge and TM CD8

Inclusion criteria:

- RRMM with ≥ 3 prior lines of therapy (including PI and immunomodulatory drugs), or 2 prior regimens if double refractory **(median: 7 lines)**



	Cohort 1 (n = 9)	Cohort 2 (n = 5)	Cohort 3 (n = 11)
Treatment	**1–5 × 10^8** CAR+ T cells	Cy 1.5 g/m^2 + **1–5 × 10^7** CAR+ T cells	Cy 1.5 g/m^2 + **1–5 × 10^8** CAR+ T cells
ORR, n (%)	**4 (44)**	1 (20)	**7 (64)**
mPFS, days	65	57	125

Cohen AD, et al. J Clin Invest. 2019;129:2210-21

BCMA CAR T cell
Ide-cel (bb2121) CRB-401 phase 1 trial



Dose escalation

≥ 50% BCMA expression

50×10^6 → 150×10^6 → 450×10^6 → 800×10^6

Inclusion criteria:

- RRMM with ≥ 3 prior lines of therapy (including PI and IMiD compounds), or double-refractory
- Measurable disease
- ≥ 50% BCMA expression
- Adequate organ function

Primary endpoint: safety (AEs, CRS, neurological toxic events)
Secondary endpoints: response rate and duration

Dose expansion

< 50% BCMA expression
≥ 50% BCMA expression
Dose range: $150–450 \times 10^6$ CAR+ cells

Inclusion criteria:

- No BCMA expression required
- **Previous exposure** to PI, IMiD compounds, and **daratumumab**
- Refractory to last line of therapy

AE, adverse event; RRMM, relapsed/refractory MM.

Raje N, et al. N Engl Med. 2019;380:1726-37.

Ide-cel CRB-401 phase 1 trial: baseline demographics and patient characteristics

Characteristic	Dose escalation (N = 21)	Expansion (N = 12)
Prior anti-myeloma regimens, median (range)	7 (3–14)	8 (3–23)
Prior ASCT, no. (%)		
0	0	1 (8)
1	15 (71)	8 (67)
≥ 2	6 (29)	3 (25)

Characteristic	Dose escalation (N = 21)		Expansion (N = 12)	
	Exposed	Refractory	Exposed	Refractory
Prior therapies, n (%)				
Bortezomib	21 (100)	13 (62)	12 (100)	7 (58)
Carfilzomib	19 (91)	12 (57)	11 (92)	7 (58)
Lenalidomide	21 (100)	17 (81)	12 (100)	7 (58)
Pomalidomide	19 (91)	14 (67)	12 (100)	12 (100)
Daratumumab	15 (71)	9 (43)	12 (100)	9 (75)
Bortezomib / Lenalidomide	21 (100)	12 (57)	12 (100)	5 (42)
Bortezomib / Lenalidomide / Carfilzomib / Pomalidomide / Daratumumab	15 (71)	3 (14)	11 (92)	3 (25)

Raje N, et al. N Engl Med. 2019;380:1726-37.

Ide-cel CRB-401 phase 1 trial: tumour response is dose-related and independent of tumour BCMA expression

Tumour response by dose



Tumour response by BCMA expression[a]



Response	50 × 10⁶	150 × 10⁶	450 × 10⁶	800 × 10⁶	Total
MRD-evaluable responders	0	4	11	1	16
MRD-neg[a]	0	4 (100)	11 (100)	1 (100)	16 (100)

mDOR, median duration of response; NE, not evaluable.

Raje N, et al. N Engl Med. 2019;380:1726-37.

Ide-cel CRB-401 phase 1 trial: tumour response by baseline characteristics



DARA, daratumumab; EMD, extramedullary disease; PD, progressive disease.

Raje N, et al. N Engl Med. 2019;380:1726-37.

Ide-cel CRB-401 phase 1 trial: AEs of special interest

CAR T cell therapy TEAEs
All infused patients (N = 33)

TEAE, n (%)	Any Grade	Grade 3	Grade 4
CRS	25 (76)	2 (6)	0
Neurological toxic effect[a]	14 (42)	0	1 (3)[b]
Neutropenia	28 (85)	2 (6)	26 (79)
Thrombocytopenia	19 (58)	5 (15)	10 (30)
Anaemia	19 (58)	15 (45)	0
Infection	12 (36)	2 (6)	0

Time to recovery of grade 3/4 cytopenia[c]



- **Relationship tumor burden-CRS risk**
- **Possible but not sure relationship CAR-T dose-CRS risk**

Raje N, et al. N Engl Med. 2019;380:1726-37.

Ide-cel CRB-401 phase 1 trial: PFS



Raje N, et al. N Engl Med. 2019;380:1726-37.

KarMMa
Ide-cel pivotal phase 2 single-arm study

KarMMa — Kar T In Multiple Myeloma

RRMM

- ≥ 3 prior treatment regimens with ≥ 2 consecutive cycles each
- **Received prior IMiD, PI, and anti-CD38**
- Refractory (per IMWG criteria) to last treatment regimen



Endpoints

Primary: ORR

Secondary: CR (key secondary), TTR, DOR, PFS, TTP, OS, safety, bb2121 expansion and persistence, MRD (genomic and flow assays), QoL, immunogenicity, cytokines

Exploratory: BCMA expression/loss, T cell immunophenotype, GEP in BM, HEOR

GEP, gene expression profile; HEOR, health economics and outcomes research; IMWG, International Myeloma Working Group; QoL, quality of life; TTP, time to progression; TTR, time to response.

ClinicalTrials.gov Identifier: NCT03361748.

LCAR-B38M BCMA CAR T
Phase I study: design (Legend-2)

- Lentiviral vector based + 4-1BB co-stimulatory domain
- BCMA catching domain target **two different epitopes simultaneously**



Key inclusion: resistant to > 3 prior lines, BCMA expression in >10% clonal PCs

Median number of prior lines of therapy: **3 (1–9)**

Prior bort: 68%; prior len: 44%; prior PI + IMiD: 60%; prior SCT: 18%

Zhao WH, et al. Presented at ASH 2018; abstract 955.

LCAR-B38M: Legend Biotech phase I trial - updated single-centre experience (LEGEND 2)

- **Conditioning**: Cyclophosphamide 300mg/m^2

- **CAR-T cells**/kg: 0.07 – 2.1 x 10^6. Median dose: 0.5 x 10^6 cells/kg
- **Split infusion** (Day 1 20%, Day 3 30%, Day 7 50%)

ORR = 88% 74% CR and 68% MRD-neg CR)



All pts:	57	53	48	37	21	11	7	4	1	0
Pts achieving MRD-neg CR:	39	39	38	33	20	10	7	4	1	0
Pts not achieving MRD-neg CR:	18	14	10	4	1	1	0	0	0	0

Zhao WH, et al. Presented at ASH 2018; abstract 955.

- mDOR = 16 mo (95% CI, 12 mo–NR)
- mDOR for MRD-neg CR: 22 mo (95% CI, 14 mo–NR)
- 12 mo OS: 75%; 94% for pts achieving MRD-neg CR
- Pts not achieving MRD-neg CR had poor outcome: mPFS 6 mo, mOS 8 mo, 12-mo OS 29%

Toxicity profile

- 35% grade 2 CRS; 7% grade 3; no grade 4
- Tocilizumab use: 46%

Ongoing trial, **phase 1b/2 CARTITUDE-1 study** (NCT03548207) evaluating **JNJ-68284528** (**same CAR as LCAR-B38M**)

Evaluate effectiveness of LCAR-B38M in more typically heavily treated US (and ex-US) patients compared to Chinese cohort

What we know: lessons from initial studies

CAR-T cell expansion correlates with response across different trials

NCI[2]



UPenn[3]



Peak ide-cel vector copies in responders vs non-responders[1]



Patients with at least 1 month of cellular kinetics data (N = 33).
The p value is based on a 2-sided Wilcoxon rank-sum test.

- Comparable C_{max} in active dose cohorts (≥ 150 × 10^6 CAR+ T cells)
- Durable ide-cel persistence (≥ 6 months) in 57%
- **Higher peak expansion in patients with response**

[1]Raje N, et al. N Engl Med. 2019;380:1726-37; [2]Brudno JN, et al. J Clin Oncol. 2018;36:2267-80; [3]Cohen AD, et al. J Clin Invest. 2019;129:2210-21.

What we know: lessons from initial studies

PFS of CAR-T cells in multiple myeloma compared with lymphoma:

Despite very high ORR and CR rates, patients continue to relapse....

bb2121 (CRB 401)



Axicabtagene ciloleucel (ZUMA-1)



Tisagenlecleucel (JULIET)



Room for improvement with CAR-T....

Different biology of myeloma v. lymphoma....

What we know: lessons from initial studies
CAR-T vs other therapies

CAR-T therapy may allow patients to step off the "treadmill" of continuous treatment

CAR T

Current paradigm of myeloma therapy:
continuous *treatment until progression*

One *treatment (then observation)*

What we know:

Not all T-cells are the same. T-cell fitness matters

% of **naive-memory CD8**+ cells in the apheresis product correlates with in vivo **expansion and response**





Patient selection: early RRMM patients after induction treatment compared to highly pretreated RRMM patients[2]



	Post-induction	Relapsed/ Refractory
Median lines of terapy (range)	1 (1-4)	7 (3-15)

Gattinoni L et al. Nature Medicine (2017); Cohen AD, et al. J Clin Invest. 2019;129:2210-21; Dancy E et al, ASH 2018, Blood 132:1886

What we do not know yet?
Understanding the non-responders and the resistance



Slide presented by N. Raje at IMW meeting in Boston, September 2019

Not all T cells are the same

Next generation of products trying to increase the % of memory Tcells

	Bb21217	JCARH125 (Orva-cel) (EVOLVE)
Binder	Murine	Human
Costimulatory domain	4-1BB	4-1BB
Vector	Lentivirus	Lentivirus
Manufacturing Process	Unselected T cells at culture initiation + **PI3K inhibitor during T cell culture**	1:1 ratio of CD4/CD8 T cells at culture initiation
T Cell Phenotype	Enriched for T_n and T_{cm} cells	Enriched for T_n and T_{cm} cells
Preclinical	Low tonic signaling No inhibition by sBCMA	Low tonic signaling No inhibition by sBCMA
Stage of Development	Phase I trial initiated Q3 2017	Phase I trial initiated Q1 2018
Preliminary efficacy results	ORR 83% $150x10^6$ CAR T 4/4 MRDneg	ORR (n=44) 79%; CR 43%

Shah N et al. Presented at ASH 2018; abstract 488
ASH 2018 Celgene investor relations event, december 2, 2018:
https://s22.q4cdn.com/728481125/files/doc_presentations/2019
/03/ASH-2018-IR-Event_FINAL_website-version_updated.pdf
Mailankody S et al.Blood;132:957. Presented at ASH 2018

MM-cell intrinsic mechanisms:
BCMA loss or modulation has been described after anti-BCMA CAR T therapy

Residual MM cells from responding patients show a lower BCMA expression 1 month after CAR-T cell infusion[2]



CARAMBA project: SLAMF-7 CAR T

SLAMF-7 targeting, virus-free Sleeping Beauty gene transfer

Expressed on a fraction of NK, T & B cells: activating or inhibitory function

High-level expression is retained in malignant plasma cells in MM and MGUS

Eradication of extra-/medullary myeloma after single dose of SLAMF7 CAR T



Cohen AD, et al. J Clin Invest. 2019;129:2210-21, Gogishvili T, et al. Blood 2017;130:2838–47.

First CAR-T in MM: CD-19

Rational: a minor component of the MM clone with drug-resistant, disease-propagating properties has a B-cell phenotype (99% PCs negative for CD19)

Study Design and Patient Characteristics

Eligibility Criteria
- Multiple Myeloma Progression within one year of prior ASCT
- Age <70
- Fit for 2nd ASCT

Salvage High-dose Melphalan + Auto-SCT → 12-14 DAYS → CTL019 5 x 10^7 cells → FOLLOW FOR PFS

Primary Endpoints
- Safety (CRS, neurotoxicity)
- Feasibility (manufacturing success)

Secondary Endpoints
- CTL019 engraftment and B cell aplasia
- Day 42 and day 100 response
- Progression-free survival (vs. last ASCT)
- Correlation of response to CD19 expression



•**12** pts enrolled → **10 pts** treated. Median of prior lines: 6

Garfall AL, et al. N Engl J Med 2015; 373:1040-1047

Garfall AL, et al. JCI Insight, 2018; 3(8):e120505

New targets and dual-target CAR-T

Infusion of anti-CD19 and anti-BCMA CAR T cells[1]



ORR 95%
(≥CR 57%)

Dual targeting anti-BCMA/anti-CD38 CAR T cells[2]



ORR 83%
(≥CR 42%)

Yan Z et al. Lancet Haematol. 2019 Aug 1; Mei H et al EHA 2019 Jun 15, 2019; 267409; S826.
ORR: overall response rate; CR: complete response. sCR: stringent complete response. VGPR: very good partial remission. PR: partial response. SD: stable disease.

Improving CAR-T function: humanized CAR-Ts

- Is there a role of host anti-CAR immunity?. Since most of the CARs have non-human domains
  ➔ Role of **fully humanized CAR-T**



The data are cut off 2019-08-29
The sensitivity of MRD assessment is $1/10^4$ cells

Best Response Achieved

ORR 100%

sCR/CR 70.6%**

VGPR or better 88.2%**

BOLD Numbers- Patients relapsed from a prior CAR-T treatment

* Patient 12 died during the trial probably due to respiratory failure resulting from a lung infection.
**For evaluable patients (n=17)

Li C. et al. Oral presentation at IMW meeting in Boston, September 2019

Development of CAR-T in MM: earlier lines of therapy

- **This is just the beginning of anti BCMA CAR-T**, "version 1.0": CAR-T for heavily pre-treated patients
  - Deep responses, but room for improvement with durability of response

- **BCMA CAR-T pivotal trials in RRMM (≥ 3 prior lines)**
  - Celgene/Bluebird; Janssen/Legend; Celgene/Juno, Poseida
  - **Regulatory approval by 2020? (FDA)**

- Potential **advantages to CAR-T earlier in patient course:**
  - **Less clonal heterogeneity**, less clonal evolution: less resistance to therapy
  - **Lower tumor burden** at first or earlier relapse
  - **Better functional status,** less comorbidities, better renal function
  - **Source of CAR-T cells may be less "exhausted**," see also comparison of T cells in healthy donors v. MGUS/myeloma patients (Bailur JK et al., *JCI Insight* 2019)

- **KarMMa-2 (**NCT03601078) in early relapse with **bb2121**
  - Early relapse defined as **PD <18 months** since start of initial therapy (with or without auto SCT)
- **KarMMa-3** (NCT03651128), randomized study of **bb2121** v. standard of care in patients with **2-4 prior lines** of treatment

Van De Donk et al. Oral presentation at IMW meeting in Boston, September 2019

CAR-T trials ongoing (2019-2020)



- **Phase 1/2 trials for next generation CAR products (i.e. BB21217, JNJ 68284528 CARTITUDE-1)**
- **BCMA CAR trials in patients in earlier lines of therapy**
  - 1-3 prior lines (randomized with SoC regimens)
  - Early relapse after optimized frontline treatment (high-risk disease)
  - Consolidation in non-CR patients with HR disease
- **New targets: SLAMF7 (CARAMBA trial), GPRC5D …**
- **Dual CAR-T**(CD19 + BCMA, CD38 + BCMA)
- **Combination trials**
  - Gammasecretase inhibitors, checlpoint, IMIDs
- **Off-the shelf allogeneic CAR-T**

Conclusion



- Despite continuous improvement in survival thanks to the incorporation of novel treatments, MM patients still relapse, and survival after failure to IMiDs, PIs and MoAbs remains poor. Therefore, there is a **need for new treatment strategies in these patients**

- **BCMA** is a promising therapeutic target and clinical results with the new **BCMA-directed treatments** are revolutionary among patients with RRMM; especially **CAR-T cells** showed the possibility to obtain **very high CR rate and MRD-neg rates.** However, **no plateau** has yet been seen in the curve

- Outcomes will be improved by understanding **the mechanisms of action, immune response and cell biology (next-generation CAR-T products)**

- CAR-T therapy should be integrated with **other TC re-directed therapies,** to define which patient may benefit from each strategy and if there is a place for **re-treatment or alternating strategies**

- **Adequate patient selection and earlier use** in the course of the disease may surely impact the long-term outcomes of these novel therapies.

Acknowledgements

Seràgnoli Institute of Hematology



Myeloma Research Unit
Prof. Michele Cavo

ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

Clinical Research Unit
Elena Zamagni
Paola Tacchetti
Lucia Pantani
Katia Mancuso
Serena Rocchi
Ilaria Rizzello
Alessio Fusco
Gabriella De Cicco
Francesco De Felice
Margherita Ursi

Data Management
Federica Pedali
Alessandra Gnani
Giorgia Lazzarini
Francesca Trombetta
Alessandra Scatà
Simona Barbato
Claudio Mustacchio

Lab of Cytogenetics
Nicoletta Testoni
Giulia Marzocchi

Lab of Molecular Biology
Carolina Terragna
Marina Martello
Vincenza Solli
Rosalinda Termini
Andrea Poletti

Lab of Cellular Biology
Enrica Borsi

Statistical Analysis
Luca Dozza